0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Observation |

Acute Generalized Exanthematous Pustulosis Induced by Sorafenib FREE

Maider Pretel, MD, PhD1; Mercedes Iñarrairaegui, MD, PhD1; José Miguel Lera, MD1; Leyre Aguado, MD, PhD1; Miguel Angel Idoate, MD, PhD2
[+] Author Affiliations
1Department of Dermatology, School of Medicine, University Clinic of Navarra, Pamplona, Spain
2Department of Pathology, School of Medicine, University Clinic of Navarra, Pamplona, Spain
JAMA Dermatol. 2014;150(6):664-666. doi:10.1001/jamadermatol.2013.6924.
Text Size: A A A
Published online

Sorafenib (Nexavar; Bayer HealthCare AG) is an oral multikinase inhibitor approved by the US Food and Drug Administration for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma. It inhibits multiple tyrosine kinases, including C-RAF and B-RAF, vascular endothelial growth factor receptors, and platelet-derived growth factor receptor (PDGFR).

Acute generalized exanthematous pustulosis (AGEP) is a rare skin eruption associated principally with drugs. To our knowledge, only 1 report of sorafenib-induced acute localized exanthematous pustulosis (ALEP) has been published.1 Herein, we report the first case of AGEP induced by sorafenib.

REPORT OF A CASE

A woman in her 50s presented with a history of multifocal hepatocarcinoma previously treated unsuccessfully with radiofrequency, arterial embolization, and selective hepatic radioembolization. After the appearance of lung metastases, treatment was begun with sorafenib (400 mg every 12 hours). Two weeks later, the patient developed hand-foot skin reaction (HSFR), so the treatment was suspended with resolution of the lesions. Treatment with the drug was reintroduced at half dose with good results, and full doses were then administered. Ten days later, the HSFR reappeared, and sorafenib treatment was suspended again. After 3 weeks, sorafenib treatment was restarted at half dose.

After 4 weeks, and without any other drug being added to the treatment regimen, the patient developed an abrupt eruption consisting of erythematous and edematous plaques with hundreds of tiny nonfollicular pustules that appeared first in the genital and inguinal areas and subsequently on the legs, abdomen, buttocks, and neck (Figure 1). She had no mucosal lesions, fever, or any other relevant symptoms. The blood neutrophil count was elevated (7.1 × 109/L), as was the eosinophil count (0.44 × 109/L). (To convert neutrophils and eosinophils to number of cells per microliter, divide by 0.001.)

Place holder to copy figure label and caption
Figure 1.
Clinical Photographs of Acute Generalized Exanthematous Pustulosis Induced by Sorafenib

A, Eruption consisting of erythematous and edematous plaques with small pustules noted on patient’s legs. B, Erythematous plaques without pustules on patient’s neck.

Graphic Jump Location

Skin biopsy revealed formation of subcorneal pustules containing neutrophil aggregates with spongiotic change in the epidermis, edema of the papillary dermis, and superficial perivascular neutrophil and lymphocyte infiltration with red blood cell extravasation in the dermis (Figure 2).

Place holder to copy figure label and caption
Figure 2.
Histopathologic Findings

Skin biopsy section showing the formation of subcorneal pustules containing neutrophil aggregates with spongiotic change in the epidermis (hematoxylin-eosin, original magnification ×200).

Graphic Jump Location

A diagnosis of AGEP was made. Sorafenib treatment was discontinued promptly. The patient’s skin lesions subsided spontaneously, and desquamation occurred a week later. Results of epicutaneous tests with sorafenib were negative at 48, 96, and 168 hours.

DISCUSSION

The most frequent adverse effects of sorafenib are those affecting the skin (up to 60% patients),2 although interestingly, some reports suggest that patients taking sorafenib for hepatocellular carcinoma who develop skin toxic effects show a longer survival.3 The pathogenic mechanism remains unclear. These adverse effects include HFSR, callosities on areas of high pressure, exanthema, itching, subungual splinter hemorrhages, alopecia, keratoacanthoma, squamous cell carcinoma, seborrheic dermatitislike eruption, and erythema multiforme.2

We describe herein a case of patient who was taking sorafenib who developed AGEP, which is a rare skin eruption characterized by an abrupt onset of edematous erythema with numerous small pustules associated principally with drugs. We know of only 1 case in the literature of the localized form of the drug eruption ALEP induced by sorafenib. We have found no cases of AGEP induced by this new drug. However, several cases of AGEP have been reported in patients receiving imatinib, which shares with sorafenib the inhibition pathway of PDGFR.4

The principal differential diagnosis of AGEP consists of pustular psoriasis. The absence of clinical history of psoriasis, the more acute course, and rapid spontaneous resolution after discontinuation of drug treatment make the diagnosis of AGEP more likely. A negative result from the patch tests does not rule out the diagnosis (only 50% of cases of AGEP show a positive result with the drug involved).5 Despite the lack of fever, considered a typical clinical feature, our case was classified as definite according to the EuroSCAR scoring system.6

Recognizing cutaneous adverse effects early and administering appropriate treatment will likely increase medication compliance and minimize dose reductions and discontinuation of the drug treatment.

ARTICLE INFORMATION

Corresponding Author: Maider Pretel, MD, PhD, Department of Dermatology, University Clinic of Navarra, Avda Pío XII s/n, 31080 Pamplona, Spain (mpretel@unav.es).

Published Online: March 26, 2014. doi:10.1001/jamadermatol.2013.6924.

Conflict of Interest Disclosures: None reported.

REFERENCES

Liang  CP, Yang  CS, Shen  JL, Chen  YJ.  Sorafenib-induced acute localized exanthematous pustulosis in a patient with hepatocellular carcinoma. Br J Dermatol. 2011;165(2):443-445.
PubMed   |  Link to Article
Bracarda  S, Ruggeri  EM, Monti  M,  et al; Sorafenib Working Group.  Early detection, prevention and management of cutaneous adverse events due to sorafenib: recommendations from the Sorafenib Working Group. Crit Rev Oncol Hematol. 2012;82(3):378-386.
PubMed   |  Link to Article
Otsuka  T, Eguchi  Y, Kawazoe  S,  et al; Saga Liver Cancer Study Group.  Skin toxicities and survival in advanced hepatocellular carcinoma patients treated with sorafenib. Hepatol Res. 2012;42(9):879-886.
PubMed   |  Link to Article
Schwarz  M, Kreuzer  KA, Baskaynak  G, Dörken  B, le Coutre  P.  Imatinib-induced acute generalized exanthematous pustulosis (AGEP) in two patients with chronic myeloid leukemia. Eur J Haematol. 2002;69(4):254-256.
PubMed   |  Link to Article
Wolkenstein  P, Chosidow  O, Fléchet  ML,  et al.  Patch testing in severe cutaneous adverse drug reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis. Contact Dermatitis. 1996;35(4):234-236.
PubMed   |  Link to Article
Sidoroff  A, Halevy  S, Bavinck  JN, Vaillant  L, Roujeau  JC.  Acute generalized exanthematous pustulosis (AGEP): a clinical reaction pattern. J Cutan Pathol. 2001;28(3):113-119.
PubMed   |  Link to Article

Figures

Place holder to copy figure label and caption
Figure 1.
Clinical Photographs of Acute Generalized Exanthematous Pustulosis Induced by Sorafenib

A, Eruption consisting of erythematous and edematous plaques with small pustules noted on patient’s legs. B, Erythematous plaques without pustules on patient’s neck.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 2.
Histopathologic Findings

Skin biopsy section showing the formation of subcorneal pustules containing neutrophil aggregates with spongiotic change in the epidermis (hematoxylin-eosin, original magnification ×200).

Graphic Jump Location

Tables

References

Liang  CP, Yang  CS, Shen  JL, Chen  YJ.  Sorafenib-induced acute localized exanthematous pustulosis in a patient with hepatocellular carcinoma. Br J Dermatol. 2011;165(2):443-445.
PubMed   |  Link to Article
Bracarda  S, Ruggeri  EM, Monti  M,  et al; Sorafenib Working Group.  Early detection, prevention and management of cutaneous adverse events due to sorafenib: recommendations from the Sorafenib Working Group. Crit Rev Oncol Hematol. 2012;82(3):378-386.
PubMed   |  Link to Article
Otsuka  T, Eguchi  Y, Kawazoe  S,  et al; Saga Liver Cancer Study Group.  Skin toxicities and survival in advanced hepatocellular carcinoma patients treated with sorafenib. Hepatol Res. 2012;42(9):879-886.
PubMed   |  Link to Article
Schwarz  M, Kreuzer  KA, Baskaynak  G, Dörken  B, le Coutre  P.  Imatinib-induced acute generalized exanthematous pustulosis (AGEP) in two patients with chronic myeloid leukemia. Eur J Haematol. 2002;69(4):254-256.
PubMed   |  Link to Article
Wolkenstein  P, Chosidow  O, Fléchet  ML,  et al.  Patch testing in severe cutaneous adverse drug reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis. Contact Dermatitis. 1996;35(4):234-236.
PubMed   |  Link to Article
Sidoroff  A, Halevy  S, Bavinck  JN, Vaillant  L, Roujeau  JC.  Acute generalized exanthematous pustulosis (AGEP): a clinical reaction pattern. J Cutan Pathol. 2001;28(3):113-119.
PubMed   |  Link to Article

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

444 Views
1 Citations

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles
Jobs
×